BR0107371A - Formulação de inìcio rápido - Google Patents
Formulação de inìcio rápidoInfo
- Publication number
- BR0107371A BR0107371A BR0107371-0A BR0107371A BR0107371A BR 0107371 A BR0107371 A BR 0107371A BR 0107371 A BR0107371 A BR 0107371A BR 0107371 A BR0107371 A BR 0107371A
- Authority
- BR
- Brazil
- Prior art keywords
- pyridoxine hcl
- doxylamine succinate
- dissolved
- minutes
- measurement
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- KBAUFVUYFNWQFM-UHFFFAOYSA-N Doxylamine succinate Chemical compound OC(=O)CCC(O)=O.C=1C=CC=NC=1C(C)(OCCN(C)C)C1=CC=CC=C1 KBAUFVUYFNWQFM-UHFFFAOYSA-N 0.000 abstract 6
- 229960005008 doxylamine succinate Drugs 0.000 abstract 6
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 abstract 6
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 abstract 6
- 239000011764 pyridoxine hydrochloride Substances 0.000 abstract 6
- 229940011671 vitamin b6 Drugs 0.000 abstract 6
- 238000005259 measurement Methods 0.000 abstract 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 238000004090 dissolution Methods 0.000 abstract 2
- 239000011230 binding agent Substances 0.000 abstract 1
- 239000002702 enteric coating Substances 0.000 abstract 1
- 238000009505 enteric coating Methods 0.000 abstract 1
- 239000000945 filler Substances 0.000 abstract 1
- 239000000314 lubricant Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000008363 phosphate buffer Substances 0.000 abstract 1
- 239000000377 silicon dioxide Substances 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Lubricants (AREA)
- Seal Device For Vehicle (AREA)
- Memory System Of A Hierarchy Structure (AREA)
- Power Steering Mechanism (AREA)
Abstract
"FORMULAçãO DE INìCIO RáPIDO". Provido aqui é uma nova formulação de início rápido de doxilamina succinato e piridoxina HC1 entericamente revestida compreendendo um agente de desintegração tal que os seguintes perfis de dissolução são satisfeitos quando medidos em 1000 ml de tampão fosfato em pH de 6.8 e 37<198>C no tipo de aparelho de dissolução 2 em 100 rpm; (a) pelo menos cerca de 40% piridoxina HC1 e doxilamina succinato total é dissolvido após 30 minutos de medição; (b) pelo menos cerca de 70% da piridoxina HC1 e doxilamina succinato total é dissolvido após 60 minutos de medição; (c) pelo menos cerca de 80% da piridoxina HC1 e doxilamina succinato total é dissolvido após 90 minutos de medição; (d) cerca de 90% da piridoxina HC1 e doxilamina succinato total é dissolvido após 120 minutos de medição. Preferivelmente a formulação pode conter um núcleo revestido com pelo menos um revestimento entérico, o núcleo compreendendo piridoxina HC1, doxilamina succinato e os seguintes excipiente não-ativos: um enchimento ou um ligante, um agente desintegrante, um lubrificante, um condicionador de fluxo de sílica e um agente estabilizante.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002350195A CA2350195C (en) | 2000-12-20 | 2000-12-20 | Rapid onset formulation of pyridoxine hydrochloride and doxylamine succinate |
PCT/CA2001/000951 WO2003000263A1 (en) | 2000-12-20 | 2001-06-21 | Rapid onset formulation |
US09/885,051 US6340695B1 (en) | 2000-12-20 | 2001-06-21 | Rapid onset formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0107371A true BR0107371A (pt) | 2003-06-10 |
Family
ID=42104724
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0107371-0A BR0107371A (pt) | 2000-12-20 | 2001-06-21 | Formulação de inìcio rápido |
Country Status (35)
Country | Link |
---|---|
US (1) | US6340695B1 (pt) |
EP (1) | EP1397133B1 (pt) |
JP (1) | JP4242763B2 (pt) |
KR (1) | KR100527985B1 (pt) |
CN (1) | CN1229112C (pt) |
AT (1) | ATE307582T1 (pt) |
AU (1) | AU2001272243B2 (pt) |
BE (1) | BE1014929A4 (pt) |
BR (1) | BR0107371A (pt) |
CA (1) | CA2350195C (pt) |
DE (2) | DE10196426T1 (pt) |
DK (2) | DK1397133T3 (pt) |
EG (1) | EG24483A (pt) |
ES (1) | ES2251494T3 (pt) |
FI (1) | FI117961B (pt) |
FR (1) | FR2826277B1 (pt) |
GB (1) | GB2383751C (pt) |
GR (1) | GR1004371B (pt) |
HK (1) | HK1052654A1 (pt) |
HU (1) | HU227003B1 (pt) |
IL (1) | IL150349A0 (pt) |
IS (1) | IS2225B (pt) |
IT (1) | ITTO20020524A1 (pt) |
LU (1) | LU90934B1 (pt) |
MC (1) | MC200059A1 (pt) |
MX (1) | MXPA02006037A (pt) |
MY (1) | MY132786A (pt) |
NL (1) | NL1020895C2 (pt) |
NO (1) | NO332190B1 (pt) |
PL (1) | PL204507B1 (pt) |
SE (1) | SE526307C2 (pt) |
TR (1) | TR200201685T1 (pt) |
UA (1) | UA74807C2 (pt) |
UY (1) | UY27352A1 (pt) |
WO (1) | WO2003000263A1 (pt) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2350195C (en) * | 2000-12-20 | 2003-06-10 | Duchesnay Inc. | Rapid onset formulation of pyridoxine hydrochloride and doxylamine succinate |
US8257746B2 (en) | 2001-04-10 | 2012-09-04 | Pernix Therapeutics, Llc | Tannate compositions, methods of making and methods of use |
US8012506B2 (en) * | 2001-04-10 | 2011-09-06 | Pernix Therapeutics, Llc | Tannate compositions, methods of making and methods of use |
ES2229876B1 (es) * | 2001-06-26 | 2006-03-01 | Duchesnay Inc. | Formulacion de accion rapida. |
CA2392486A1 (en) * | 2002-07-05 | 2002-12-08 | Duchesnay Inc. | Pharmaceutical dosage form bearing pregnancy-friendly indicia |
CA2406592C (en) * | 2002-10-04 | 2003-09-30 | Duchesnay Inc. | Method of preparing pharmaceutical dosage forms containing multiple active ingredients |
JP2004231520A (ja) * | 2003-01-28 | 2004-08-19 | Nichiko Pharmaceutical Co Ltd | 保存安定性及び溶出速度に優れた医薬組成物 |
US20050004181A1 (en) * | 2003-07-03 | 2005-01-06 | Duchesnay Inc. | Use of anti-emetic for pre and post operative care |
EP1830886B1 (en) | 2004-12-27 | 2016-04-13 | Eisai R&D Management Co., Ltd. | Method for stabilizing anti-dementia drug |
US20090208579A1 (en) * | 2004-12-27 | 2009-08-20 | Eisai R & D Management Co., Ltd. | Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same |
US20060280789A1 (en) * | 2004-12-27 | 2006-12-14 | Eisai Research Institute | Sustained release formulations |
US20070129402A1 (en) * | 2004-12-27 | 2007-06-07 | Eisai Research Institute | Sustained release formulations |
CN101166543B (zh) * | 2005-04-28 | 2014-07-16 | 卫材R&D管理有限公司 | 含抗痴呆药物的组合物 |
US20070277530A1 (en) * | 2006-05-31 | 2007-12-06 | Constantin Alexandru Dinu | Inlet flow conditioner for gas turbine engine fuel nozzle |
CN102108059B (zh) * | 2010-09-03 | 2012-05-09 | 合肥工业大学 | 一种琥珀酸多西拉敏的合成方法 |
US8950188B2 (en) | 2011-09-09 | 2015-02-10 | General Electric Company | Turning guide for combustion fuel nozzle in gas turbine and method to turn fuel flow entering combustion chamber |
SG11201403931YA (en) | 2012-02-22 | 2014-08-28 | Duchesnay Inc | Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof |
WO2013123569A1 (en) * | 2012-02-22 | 2013-08-29 | Duchesnay Inc. | Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof |
US10952968B2 (en) | 2012-05-14 | 2021-03-23 | Shionogi & Co., Ltd. | Preparation containing 6,7-unsaturated-7-carbamoyl morphinan derivatives |
US9452181B2 (en) | 2013-07-22 | 2016-09-27 | Duchesnay Inc. | Composition for the management of nausea and vomiting |
EP3024466B1 (en) * | 2013-07-22 | 2018-04-04 | Duchesnay Inc. | Composition for the management of nausea and vomiting |
CN103432126A (zh) * | 2013-08-05 | 2013-12-11 | 北京阜康仁生物制药科技有限公司 | 一种治疗孕吐的药物组合物 |
TWI595874B (zh) | 2014-08-29 | 2017-08-21 | 達契斯奈股份有限公司 | 多西拉敏及吡哆醇及/或其代謝產物或鹽之多模式釋放調配物 |
JP6272561B2 (ja) | 2014-08-29 | 2018-01-31 | デュシネイ・インコーポレイテッド | ドキシラミン並びにピリドキシン及び/またはそれらの代謝産物もしくは塩の多峰性放出製剤 |
WO2017029573A1 (en) | 2015-08-17 | 2017-02-23 | Aequus Pharmaceuticals Inc. | Transdermal delivery of doxylamine succinate and pyridoxine hydrochloride |
CN105510512B (zh) * | 2016-01-25 | 2018-06-29 | 南京济群医药科技股份有限公司 | 一种琥珀酸多西拉敏有关物质的rt-hplc检测方法 |
ES2847648T3 (es) * | 2018-09-27 | 2021-08-03 | Inibsa Ginecologia S A | Procedimiento para la preparación de una forma de dosificación oral de múltiples unidades de liberación modificada de succinato de doxilamina y clorhidrato de piridoxina |
CN114099450A (zh) * | 2020-08-31 | 2022-03-01 | 长春海悦药业股份有限公司 | 一种比拉斯汀片及其制备方法 |
AU2021225255B1 (en) * | 2021-09-03 | 2022-06-16 | Patel, Mihir MR | Compositions, kits, and methods to provide synergistic and/or additive effects from comprised ingredients for the prevention, treatment and management of nausea and vomiting. |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2085641A1 (en) * | 1970-04-20 | 1971-12-31 | Investigations Sci Pharm | Noramidopyrine doxylamine succinate compsn - antiinflammatories analgesics and antipyretics |
US4642231A (en) * | 1983-07-20 | 1987-02-10 | Warner-Lambert Company | Magnesium trisilicate suitable for preparation of medicament adsorbates of antihistamines |
EP0620728B1 (en) * | 1992-01-13 | 1997-01-08 | Pfizer Inc. | Preparation of tablets of increased strength |
CA2139896C (en) * | 1995-01-10 | 2000-03-28 | Don B. Mcdonah | Use of antinauseant agent for terminally ill humans |
US6013280A (en) * | 1997-10-07 | 2000-01-11 | Fuisz Technologies Ltd. | Immediate release dosage forms containing microspheres |
WO2001019901A2 (en) * | 1999-09-14 | 2001-03-22 | Smithkline Beecham Corporation | Process for making aqueous coated beadlets |
CA2350195C (en) * | 2000-12-20 | 2003-06-10 | Duchesnay Inc. | Rapid onset formulation of pyridoxine hydrochloride and doxylamine succinate |
-
2000
- 2000-12-20 CA CA002350195A patent/CA2350195C/en not_active Expired - Lifetime
-
2001
- 2001-06-21 HU HU0301950A patent/HU227003B1/hu unknown
- 2001-06-21 IL IL15034901A patent/IL150349A0/xx active IP Right Grant
- 2001-06-21 DE DE10196426T patent/DE10196426T1/de not_active Ceased
- 2001-06-21 DE DE60114475T patent/DE60114475T2/de not_active Expired - Lifetime
- 2001-06-21 BR BR0107371-0A patent/BR0107371A/pt not_active Application Discontinuation
- 2001-06-21 PL PL362763A patent/PL204507B1/pl unknown
- 2001-06-21 GB GB0213990A patent/GB2383751C/en not_active Expired - Lifetime
- 2001-06-21 EP EP01951259A patent/EP1397133B1/en not_active Expired - Lifetime
- 2001-06-21 AU AU2001272243A patent/AU2001272243B2/en not_active Expired
- 2001-06-21 US US09/885,051 patent/US6340695B1/en not_active Expired - Lifetime
- 2001-06-21 MX MXPA02006037A patent/MXPA02006037A/es active IP Right Grant
- 2001-06-21 JP JP2003506908A patent/JP4242763B2/ja not_active Expired - Fee Related
- 2001-06-21 ES ES01951259T patent/ES2251494T3/es not_active Expired - Lifetime
- 2001-06-21 AT AT01951259T patent/ATE307582T1/de active
- 2001-06-21 TR TR2002/01685T patent/TR200201685T1/xx unknown
- 2001-06-21 KR KR10-2002-7009679A patent/KR100527985B1/ko active IP Right Review Request
- 2001-06-21 UA UA2002065093A patent/UA74807C2/uk unknown
- 2001-06-21 WO PCT/CA2001/000951 patent/WO2003000263A1/en active IP Right Grant
- 2001-06-21 DK DK01951259T patent/DK1397133T3/da active
- 2001-06-21 CN CNB018145485A patent/CN1229112C/zh not_active Expired - Fee Related
-
2002
- 2002-06-07 IS IS6412A patent/IS2225B/is unknown
- 2002-06-12 GR GR20020100280A patent/GR1004371B/el unknown
- 2002-06-18 NL NL1020895A patent/NL1020895C2/nl not_active IP Right Cessation
- 2002-06-18 IT IT2002TO000524A patent/ITTO20020524A1/it unknown
- 2002-06-19 MY MYPI20022296A patent/MY132786A/en unknown
- 2002-06-19 EG EG2002060693A patent/EG24483A/xx active
- 2002-06-20 MC MC2486A patent/MC200059A1/xx unknown
- 2002-06-20 NO NO20022982A patent/NO332190B1/no not_active IP Right Cessation
- 2002-06-20 DK DK200200947A patent/DK176018B1/da not_active IP Right Cessation
- 2002-06-20 FR FR0207643A patent/FR2826277B1/fr not_active Expired - Lifetime
- 2002-06-20 BE BE2002/0397A patent/BE1014929A4/fr not_active IP Right Cessation
- 2002-06-21 LU LU90934A patent/LU90934B1/fr active
- 2002-06-21 UY UY27352A patent/UY27352A1/es not_active Application Discontinuation
- 2002-07-03 SE SE0202061A patent/SE526307C2/sv unknown
- 2002-09-25 FI FI20021708A patent/FI117961B/fi not_active IP Right Cessation
-
2003
- 2003-07-11 HK HK03105025A patent/HK1052654A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0107371A (pt) | Formulação de inìcio rápido | |
BR9912672A (pt) | Prevenção de produção de muco no trato respiratório por administração de antagonistas de egf-r | |
BR0013720A (pt) | Formulação em pelota de liberação controlada | |
BR0007504A (pt) | Composto triazol, fármaco, e, uso de pelo menos um composto | |
BR0212586A (pt) | Composição, uso de uma combinação de ipratrópio ou um sal deste e de xilometazolina ou um sal desta, e, métodos para o tratamento de uma condição selecionada ao grupo que consiste de sintomas associados com o resfriado comum e sintomas associaods com a rinite e para estabilizar uma solução aquosa de ipratrópio ou um sal deste e xilometazolina ou um sal desta | |
NO992097L (no) | Polymerholdig preparat med kontrollert avgivelse av aktiv forbindelse | |
BR9810984A (pt) | Composto de triazol, uso do mesmo, e, composição farmacêutica | |
BR0109729A (pt) | Uso de uma combinação de um agente anti-angiogênico e um agente anti-hipertensivo, kit para uso na produção de um efeito anti-angiogênico e/ou efeito redutor da permeabilidade vascular em um animal de sangue quente, e, método de tratamento de um estado doentio associado com a angiogênese | |
BR0110400A (pt) | Método e sistema de software de aplicação ativado por rede | |
TR200103186T2 (tr) | MEK enzimlerinin inhibitörleri olarak kinolin türevleri | |
BRPI0015061B8 (pt) | comprimido revestido tendo alta dosagem de cloridrato de sevelamer | |
BR0108753A (pt) | Corpos sólidos | |
BR0003233A (pt) | Pirazol, uso do composto na preparação de um medicamento e composição | |
NO992098L (no) | Preparat med regulert avgivelse av aktiv forbindelse | |
BR0204573A (pt) | Composição para redução da irritação cutânea enzimática | |
BR0011209A (pt) | Método para o tratamento de queratina e método para aumentar o teor de cálcio da queratina | |
PT1216035E (pt) | Preparacao que contem ingredientes activos e/ou agentes auxiliares com uma libertacao controlada destas substancias e a utilizacao e producao das mesmas | |
AR034380A1 (es) | Formulacion de accion rapida | |
PT1080050E (pt) | Agente anti-retraccao para betao ou argamassa | |
BR9803319A (pt) | Uso de inibidores do trocador sódio-hidrogênio paros indesejados de substâncias sobre o coração. | |
BR0115634A (pt) | Composição anti-deslizamento para remoção de revestimento de piso | |
BRPI0405179A (pt) | Composição cosmética, kit, processo de modelagem permanente de matérias queratìnicas, uso de uma amina secundária ou terciária e agente ativo de modelagem permanente de fibras queratìnicas | |
Harrison | Plastering and internal rendering: workmanship (Part 2) | |
UA35999A (uk) | Будівельний розчин для оздоблювальних робіт | |
BRPI0315657B8 (pt) | formulação de dosagem sólida, comprimido para liberação controlada, método de fabricar uma medicação de liberação controlada, composição farmacêutica e uso de uma composição |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06G | Technical and formal requirements: other requirements [chapter 6.7 patent gazette] |
Free format text: ATRAVES DA PETICAO INPI - RJ NO 65968 DE 05/12/2002, O QUERENTE SOLICITOU O EXAME DO PRESENTE E EFETUOU A RETRIBUICAO EQUIVALENTE A 16 REIVINDICACOES. NO ENTANTO, NO ATO DO DEPOSITO ( PETICAO NO 006304 DE 24/06/2002 ) FORAM APRESENTADOS DOIS QUADROS REIVINDICATORIOS, UM COM 16 REIVINDICACOES E OUTRO COM REIVINDICACOES EMENDADAS COM TRADUCAO SIMPLES, CONSTANDO 18 REIVINDICACOES. DESSE MODO, A FIM DE DAR CONTINUIDADE AO EXAME DO PEDIDO, O REQUERENTE DEVERA COMPLEMENTAR A RETRIBUICAO EQUIVALENTE A 2 REIVNDICACOES EXCEDENTES. |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |